BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.17 +2.52%
Revenue Growth %: +3.9%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +3.9%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Five Below raises full-year outlook after strong second-quarter sales growth
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
